Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 18/20 | 0.69 |
| ▸ | ITGA2B | P08514 | 10/20 | 0.69 |
| ▸ | ITGAV | P06756 | 10/20 | 0.67 |
| ▸ | ITGB5 | P18084 | 9/20 | 0.67 |
| ▸ | ITGB1 | P05556 | 3/20 | 0.67 |
| ▸ | ITGA5 | P08648 | 3/20 | 0.67 |
| ▸ | ITGB6 | P18564 | 3/20 | 0.67 |
| ▸ | ITGB8 | P26012 | 3/20 | 0.67 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL31614099 | 1.00 | ITGB3 (0.69) | ITGB3ITGA2BITGAVITGB5ITGB1 | |
| Trifluoroacetic Acid SCHEMBL29488627 | 0.96 | ITGB3 (0.64) | ITGB3ITGA2BITGAVITGB5ITGB1 | |
| SCHEMBL29686672 | 0.95 | ITGB3 (0.75) | ITGB3ITGA2BITGAVITGB5ITGA5 | |
| Trifluoroacetic Acid SCHEMBL29992576 | 0.94 | ITGB3 (0.75) | ITGB3ITGA2BITGAVITGB5ITGB1 | |
| Trifluoroacetic Acid SCHEMBL20917265 | 0.94 | ITGB3 (0.75) | ITGB3ITGA2BITGAVITGB5ITGB1 | |
| SCHEMBL29366713 | 0.89 | ITGB3 (0.74) | ITGB3ITGA2BITGAVITGB5ITGB1 | |
| SCHEMBL17364341 | 0.89 | ITGB3 (0.74) | ITGB3ITGA2BITGAVITGB5ITGB1 | |
| SCHEMBL10049951 | 0.86 | ITGB3 (0.60) | ITGB3ITGA2BITGAVITGB5ITGA5 | |
| SCHEMBL31294830 | 0.84 | ITGB3 (0.80) | ITGB3ITGA2BITGAVITGB5ITGB1 | |
| SCHEMBL29464836 | 0.81 | ITGB3 (0.75) | ITGB3ITGA2BITGAVITGB5ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| CN-112391347-B | Magneto-optical composite nanostructures, methods of making the same, and methods of detecting, separating, or imaging analytes | 高丽大学校产学协力团 | 2024-02-20 | — | — | CN | disclosed |
| US-11779896-B2 | Magnetic-optical composite nanostructure | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2023-10-10 | — | — | US | disclosed |
| US-20230210996-A1 | NANOSATELLITE-SUBSTRATE COMPLEX AND METHOD OF REGULATING MACROPHAGE ADHESION AND POLARIZATION USING THE SAME | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2023-07-06 | — | — | US | disclosed |
| US-20230210992-A1 | NANOSATELLITE-SUBSTRATE COMPLEX AND METHOD OF REGULATING STEM CELL ADHESION AND DIFFERENTIATION USING THE SAME | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210992-A1 | NANOSATELLITE-SUBSTRATE COMPLEX AND METHOD OF REGULATING STEM CELL ADHESION AND DIFFERENTIATION USING THE SAME | EPCAM, L1CAM, NES | ITGB3 45/4885ITGA2B 46/4885ITGAV 131/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | ITGB3 1125/4885ITGA2B 1286/4885ITGAV 1364/4885 |
| US-20230210996-A1 | NANOSATELLITE-SUBSTRATE COMPLEX AND METHOD OF REGULATING MACROPHAGE ADHESION AND POLARIZATION USING THE SAME | CD14, MSR1, SLC11A2 | ITGB3 35/4885ITGA2B 47/4885ITGAV 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.